Commentary on ICH guideline on genomic sampling and data management‐enabling opportunities in drug development and patient treatment. Issue 8 (18th May 2020)

• Record Type: Journal Article
• Authors: Ehmann, Falk; Aerssens, Jeroen; Blanchard, Rebecca
• Is Part Of: British journal of clinical pharmacology. Volume 86:Issue 8(2020)
• Page Start: 1454
• Page End: 1464
• Publication Date: 2020-05-18
• Subjects: drug development -- genomic data management -- genomic sampling -- ICH E18; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.14305
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : The ability to benefit from knowledge of human genomic data in medicine has been anticipated since the sequencing of the human genome. That promise has experienced some degree of realization, particularly in oncology where biomarker‐specific clinical trials and patient treatment specific to the genetics of their tumours now occur. With whole genome sequencing and related technologies becoming more affordable, and the generation and management of vast amounts of data and information, more capable, new opportunities to benefit from these developments lie ahead. Already emerging are many studies describing the association of genomic variation with molecular underpinnings of disease, association with patient response to drugs and informing the nomination of new drug targets. These developments are accompanied by some ethical, legal and regulatory challenges, which we discuss in this article.